Summarized by Masters of Longevity from PR Newswire.
Company closed NT$900 million Series B to fund clinical oncology programs.

Key Takeaways
- Onward Therapeutics raised NT$900 million for clinical programs.
- OT-A201 showed preliminary tumor responses with manageable safety.
- OT-C001 reported favorable safety and several complete responses.



